Provided by Tiger Trade Technology Pte. Ltd.

Ensysce Biosciences Inc.

0.3733
-0.0045-1.19%
Post-market: 0.3636-0.0097-2.60%19:41 EDT
Volume:778.03K
Turnover:285.13K
Market Cap:7.26M
PE:-0.20
High:0.3745
Open:0.3705
Low:0.3624
Close:0.3778
52wk High:2.75
52wk Low:0.2300
Shares:19.46M
Float Shares:15.36M
Volume Ratio:0.15
T/O Rate:5.07%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.9099
EPS(LYR):-3.9790
ROE:-1295.09%
ROA:-185.51%
PB:-9.29
PE(LYR):-0.09

Loading ...

Ensysce Biosciences Director Bob G. Gower Acquires Common Shares Worth $443,025.17

Reuters
·
Aug 18

Heart Drug Developer Atrium Therapeutics' Q2 Loss Widens as Expenses Rise

Reuters
·
Aug 14

Ensysce Biosciences Q2 EPS $(0.20) Beats $(0.50) Estimate, Sales $1.164M Beat $1.000M Estimate

Benzinga Earnings
·
Aug 14

Ensysce Biosciences Q2 Net Loss Widens on Higher R&D Costs

Reuters
·
Aug 14

Ensysce Biosciences Q2 EPS USD -0.2

THOMSON REUTERS
·
Aug 14

Ensysce Biosciences Files Form 3 for President, Director James William Morrison

Reuters
·
Aug 11

Ensysce Biosciences Inc Expected to Post a Loss of 50 Cents a Share - Earnings Preview

Reuters
·
Aug 07

NASDAQ Trade Halt Volatility Trading Pause at 09:42 Am

Reuters
·
Aug 06

Ensysce Biosciences Posts Investor Presentation Spotlighting Trypsin-Controlled Opioid Platforms, Pain Pipeline

Reuters
·
Aug 06

Ensysce Biosciences Completes Cy Biopharma Acquisition

Reuters
·
Aug 06

Top Premarket Gainers

MT Newswires Live
·
Aug 04

Ensysce Biosciences COO Jeffrey Millard Resigns

Reuters
·
Jul 16

Ensysce Biosciences: Awarded $5.3 Mln Installment in Nida Funding Completing Multi-year $15 Mln Federal Grant

THOMSON REUTERS
·
Jul 14

Ensysce Biosciences enrolls first patient in final stage of PF614-MPAR-102

TIPRANKS
·
Jun 26

Ensysce Enrolls First Patient in Final Phase of Pf614-mpar-102 Overdose-protection Trial

Reuters
·
Jun 26

Ensysce Biosciences Files for Sale of 1.3 Million Shares

MT Newswires Live
·
Jun 05

Ensysce Biosciences files to sell 1.3M shares of common stock for holders

TIPRANKS
·
Jun 05

Ensysce Biosciences faces Nasdaq delisting risk over $2.5 million equity shortfall

Reuters
·
May 23

Ensysce Biosciences posts investor presentation on trypsin-controlled opioids with abuse, overdose protection

Reuters
·
May 19

Ensysce Biosciences Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 16